CagriSema Blend

CagriSema Blend, a dual-pathway peptide complex combining cagrilintide (5mg) and semaglutide (5mg) studied for amylin/calcitonin and GLP-1 receptor co-activation in metabolic research. 10mg total lyophilized powder, 99%+ purity per component verified by Janoshik Analytical via HPLC and mass spectrometry.

• For laboratory research use only.

• Not for human or veterinary use.

• Not intended for diagnosis, treatment, cure, or prevention of any disease.

• Use only in controlled laboratory settings by qualified personnel following appropriate safety procedures.

CagriSema is the research designation for a fixed-dose combination of two synthetic peptides — cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist). Originally developed by Novo Nordisk and currently progressing through Phase 3 clinical trials (REDEFINE 1, REDEFINE 2, REIMAGINE 2), this combination is among the most closely watched investigational compounds in modern metabolic research. Published Phase 3 data in the New England Journal of Medicine (2025) reported a 20.4% mean body weight reduction in the combination arm versus 3.0% with placebo over 68 weeks. Durham Peptides also carries Semaglutide and Tirzepatide individually for researchers interested in single-pathway or dual-agonist studies.

BENEFITS

• Dual-pathway research — amylin/calcitonin (cagrilintide) + GLP-1 (semaglutide) co-activation in one vial

• Investigational reference — corresponds to Novo Nordisk’s CagriSema clinical program

• Convenience — two compounds in a single vial, eliminating dual-vial reconstitution

• Synergy modeling — published Phase 3 data demonstrates combination effects exceed monotherapy

• Once-weekly profile — both components feature fatty-acid lipidation supporting extended half-life research

WHAT RESEARCHERS LOOK AT

• Cagrilintide: amylin and calcitonin receptor activation, brainstem satiety pathways

• Semaglutide: GLP-1 receptor agonism, hypothalamic appetite suppression

• Combined vs. monotherapy comparisons in Phase 1-3 clinical research data

• Glucagon suppression and gastric emptying delay (cagrilintide) vs. insulin secretion modulation (semaglutide)

• Weight loss curves, lipid parameters, and cardiometabolic markers in published trials

QUICK SPECS

• Form: Lyophilized peptide blend

• Net per vial: 10 mg total (Cagrilintide 5mg + Semaglutide 5mg)

• Purity: ≥99% per component (HPLC verified)

• Identity: MS-verified for both components (per COA)

• Storage: 2–8°C short-term, -20°C long-term, protect from light and moisture

• Reconstitution: Use bacteriostatic water (sold separately)

IDENTITY BASICS

• Components: Cagrilintide (CAS 1415456-99-3) + Semaglutide (CAS 910463-68-2)

• Cagrilintide molecular weight: ~3,706 g/mol (long-acting amylin analog)

• Semaglutide molecular weight: 4,113.6 g/mol (GLP-1 receptor agonist)

• Blend total: 10 mg per vial (5mg + 5mg, 1:1 ratio)

• Research designation: CagriSema